Compare · GLP-1 agonist
Liraglutide vs Orforglipron
Both are glp-1 agonist compounds. Here's how they line up on the evidence — graded the same way.
| Liraglutide | Orforglipron | |
|---|---|---|
| Evidence | 10/10 | 9/10 |
| Class | GLP-1 agonist | GLP-1 agonist |
| Summary | A once-daily GLP-1 drug with large RCT support for glucose control, weight loss, and lower cardiovascular risk in high-risk type 2 diabetes. | An oral, non-peptide (small-molecule) GLP-1 receptor agonist, FDA-approved in April 2026 as Foundayo for chronic weight management. It is a once-daily pill with no food or timing restrictions — not a peptide, and not an injectable. |
| Full profile → | Full profile → |
Liraglutide
Liraglutide is one of the most thoroughly studied metabolic drugs of the last fifteen years, and it's the direct predecessor to semaglutide. Its two approved uses rest on large, repeated, double-blind randomized trials (carefully controlled studies where neither patients nor doctors know who got…
Orforglipron
Orforglipron (brand name Foundayo) belongs to the same drug family as semaglutide and tirzepatide — a group called GLP-1 receptor agonists (drugs that copy a natural gut hormone to curb appetite and steady blood sugar). But it has one big difference: it is a small molecule rather than a peptide (a…